Combinatorial tumor suppressor inactivation efficiently initiates lung adenocarcinoma with therapeutic vulnerabilities
M. Yousefi, G. Boross, C. Weiss, C. W. Murray, J. D. Hebert, H. Cai, E. L. Ashkin, S. Karmakar, L. Andrejka, L. Chen, M. Wang, M. K. Tsai, W.-Y. Lin, C. Li, P. Yakhchalian, , M. M. Winslow
This study identifies RAS/PI3K pathway activation as a common driver in oncogene-negative lung adenocarcinomas and shows these tumors are vulnerable to targeted therapy.
bioRxiv · Oct 20, 2021Cancer Biology